Parexel establishes alliance with Catalent Pharma Solutions to streamline clinical trial material supply chain process

Boston, MA., October 03, 2012 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has established an alliance with Catalent Pharma Solutions, a global leader in development solutions and advanced drug delivery technologies. PAREXEL and Catalent have aligned their core competencies to provide a fully integrated, end-to-end clinical trial material supply chain solution. This solution will help streamline the clinical supply process and reduce timelines, while enhancing patient safety and improving service quality.

"We have seen demand from clients for a robust solution that can address the challenge of efficiently managing clinical trial material logistics across large numbers of global sites" commented Kurt Norris, Corporate Vice President and Worldwide Head of Clinical Logistics Services, PAREXEL. "In establishing this alliance with Catalent, we are uniquely positioned to help companies reach critical development milestones sooner through more efficient manufacturing, packaging and delivery of clinical trial material supplies."

  "As clinical trials become more complex, we feel it is imperative to help sponsors devise supply strategies and organize consistent manufacturing, packaging, and delivery of trial-related supplies to locations around the world," stated Gerry Hepburn, Chief Operating Officer and Vice President/General Manager of Clinical Supply Services at Catalent. "PAREXEL, with its extensive track record in clinical development and clinical trial material supply chain expertise, is the ideal partner for Catalent in this alliance, which will enable our customers to compete more effectively in the global marketplace." 

The alliance will drive greater efficiency for biopharmaceutical sponsors worldwide.  Combining PAREXEL's established clinical trial management services and global clinical logistics capabilities with Catalent's manufacturing, packaging and labeling solutions, the alliance can help ensure that clinical trial materials are in the right place at the right time.



About Catalent Pharma Solutions

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products.  With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit

more products. better treatments. reliably supplied.™

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 51 countries around the world, and has approximately 12,695 employees. For more information about PAREXEL International visit

PAREXEL is a registered trademark and PAREXEL MyTrials is a trademark of PAREXEL International Corporation and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.